Health Canada has proposed a regulatory pathway for a new class of cannabis products known as Cannabis Health Products (CHPs). On June 19, 2019, Health Canada started a consultation on potential market for CHPs that would not require a practitioner’s oversight. Health Canada are accepting comments until September 3, 2019. There is

Medicinal cannabis is being made available under a pilot programme. The pilot programme which allows access to cannabis-based products for medical use has been launched by the Minister for Health, Simon Harris. Legislation giving the go ahead for the Medical Cannabis Access Programme to operate in Ireland was signed yesterday by Simon

The European Medicines Agency (EMA) announced on Tuesday that Luxembourg and The Netherlands have now joined the mutual recognition agreement for Good Manufacturing Practice (GMP) inspections between the US Food and Drug Administration (FDA) and EU member states. This announcement comes six months after Cyprus and Bulgaria joined the agreement. The MRA,

Now featuring in this month's in-flight Aer Lingus Cara magazine, an interview with our CEO, Ann McGee. The interview titled 'A day in the life' comes following our win at the 'Aer Lingus Start Up Awards 2018'. The interview provides a great insight into the daily routine of Ann and her busy

Following the European Medicines Agency leaving its London premises on 1 March, the agency is now operating from Amsterdam. The staff will gradually move into the Spark building in Amsterdam Sloterdijk. The EMA has been working hard with the Dutch authorities to ensure these temporary premises would be ready to move into

In relation to the decision on whether a deal will be made or not on Brexit, the outcome will have a big threat on pharmaceutical research and manufacturing in the United Kingdom, the industry has said. This will potentially be driving up manufacturing costs and minimising future investment. A range of companies

The EU Mutual Recognition Agreement (MRA) with the USA was increased by two further countries. The companies that have been included are Poland and Slovenia. At present, there is a total of 22 countries recognised. Germany is still missing from this Mutual Recognition. A deadline has been established for all authorities and

There is still a very strong possibility that there will be a “Hard Brexit”. The term “Hard Brexit” refers to the United Kingdom leaving the European Union without a deal. The UK Government is now preparing legislation to allow the continued sale of and access to medicines manufactured in the remaining EU.

The European Medicines Agency has begun the process of relocating to their new headquarters located in Amsterdam. The EMA will leave its premises in London on the 1st March 2019. They will temporarily move over to the 'Spark Building' (Orlyplein 24, 1043 DP Amsterdam, The Netherlands). This temporary location will hold visits

With the prospect of a hard Brexit growing more likely by the day, Mias Pharma’s offering to the market could hardly have been timelier. The company offers pharmaceutical firms from outside Europe access to the single market and European Economic Area (EEA) by providing them with the required manufacturing and importation authorisations.